Scholarlink

Background <p>Decompressive craniectomy (DC) is a life-saving procedure for neurocritical patients with conditions such as severe traumatic brain injury (TBI), ischemic stroke, and subarachnoid hemorrhage. However, it results in cranial defects that necessitate cranioplasty to restore skull integrity, protect brain function, and address cosmetic concerns. The choice of material—autologous bone (AB) or artificial materials like titanium mesh (TM)—remains controversial due to varying complication rates.</p> Methods <p>This comparative cross-sectional study evaluated 23 patients who underwent cranioplasty with AB (n = 5) or TM (n = 18) between January 2022 and March 2025 at SVP Hospital and NHL Medical College, Ahmedabad. Data on demographics, surgical timing, complications, and outcomes were analyzed. Complications included infections, bone flap resorption (BFR), wound dehiscence, and cosmetic outcomes.</p> Results <p>The overall complication rate was 43.47% (AB group: 80%, TM group: 33.33%). BFR occurred exclusively in the AB group (40%), while TM-related complications included surgical site infections, wound dehiscence, and persistent tenderness. Wound dehiscence and multiple bone fragments were significant risk factors for post-cranioplasty infections and BFR, respectively. Cosmetic satisfaction was comparable between groups (82.60% overall), but TM demonstrated shorter operation times, reduced bleeding, and shorter hospital stays.</p> Conclusion <p>Cranioplasty using TM showed advantages over AB in terms of lower complication rates, reduced operative time, and improved hospitalization outcomes. However, TM was associated with higher minor complications like wound dehiscence. For patients with larger bone defects, artificial materials may reduce BFR risks. Further prospective randomized trials are needed to validate these findings and optimize cranioplasty outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of cranioplasty using autologous bone or titanium mesh following decompressive craniectomy: differences in complications

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月6日

查看全文
  • Renish Padshala,
  • M. D. Nazar Imam,
  • Varshesh Shah,
  • Krushi Soladhra,
  • Dharmikkumar Velani,
  • Aravindkumar Verma,
  • Jaimin Modh,
  • Kalpesh Shah,
  • Kushal Shah

摘要

Background

Decompressive craniectomy (DC) is a life-saving procedure for neurocritical patients with conditions such as severe traumatic brain injury (TBI), ischemic stroke, and subarachnoid hemorrhage. However, it results in cranial defects that necessitate cranioplasty to restore skull integrity, protect brain function, and address cosmetic concerns. The choice of material—autologous bone (AB) or artificial materials like titanium mesh (TM)—remains controversial due to varying complication rates.

Methods

This comparative cross-sectional study evaluated 23 patients who underwent cranioplasty with AB (n = 5) or TM (n = 18) between January 2022 and March 2025 at SVP Hospital and NHL Medical College, Ahmedabad. Data on demographics, surgical timing, complications, and outcomes were analyzed. Complications included infections, bone flap resorption (BFR), wound dehiscence, and cosmetic outcomes.

Results

The overall complication rate was 43.47% (AB group: 80%, TM group: 33.33%). BFR occurred exclusively in the AB group (40%), while TM-related complications included surgical site infections, wound dehiscence, and persistent tenderness. Wound dehiscence and multiple bone fragments were significant risk factors for post-cranioplasty infections and BFR, respectively. Cosmetic satisfaction was comparable between groups (82.60% overall), but TM demonstrated shorter operation times, reduced bleeding, and shorter hospital stays.

Conclusion

Cranioplasty using TM showed advantages over AB in terms of lower complication rates, reduced operative time, and improved hospitalization outcomes. However, TM was associated with higher minor complications like wound dehiscence. For patients with larger bone defects, artificial materials may reduce BFR risks. Further prospective randomized trials are needed to validate these findings and optimize cranioplasty outcomes.